We’re pleased to share a video interview with our CEO, Dr James Garner on Proactive Investors following the recent commencement of the GBM AGILE study, which will serve as the pivotal study for registration of our lead candidate, paxalisib.
Our CEO, Dr James Garner was recently interviewed on Ausbiz to discuss Kazia’s entitlement offer, with the company successfully completing the institutional component of the offer last week, which raised $16.4 million.
Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney NSW 2000, Australia
Which of the following group do you best fit?
Subscribe to our Email Alerts